Economic evaluations of radioembolization with Itrium-90 microspheres in hepatocellular carcinoma: a systematic review

[1] Forner A(2018)Hepatocellular carcinoma Lancet Lond Engl 391 1301-1314

[2] Reig M(2021)Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH Med Clin (Barc) 156 463.e1-463.e30

[3] Bruix J(2019)Humanistic and economic burden of hepatocellular carcinoma: systematic literature review Am J Manag Care 25 SP61-73

[4] Reig M(2016)Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma Gastroenterology 151 1155-1163.e2

[5] Forner A(2014)Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization Hepatol Baltim Md 59 1864-1873

[6] Ávila MA(2017)Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial Lancet Oncol 18 1624-1636

[7] Ayuso C(2018)SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-pacific patients with hepatocellular carcinoma J Clin Oncol 36 1913-1921

[8] Mínguez B(2019)Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma J Hepatol 71 1164-1174

[9] Varela M(2010)A proposed guideline for economic evaluation of health technologies Gac Sanit 24 154-170

[10] Kohn CG(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 b2535-372

[1] Forner A(2018)Hepatocellular carcinoma Lancet Lond Engl 391 1301-1314

[2] Reig M(2021)Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH Med Clin (Barc) 156 463.e1-463.e30

[3] Bruix J(2019)Humanistic and economic burden of hepatocellular carcinoma: systematic literature review Am J Manag Care 25 SP61-73

[4] Reig M(2016)Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma Gastroenterology 151 1155-1163.e2

[5] Forner A(2014)Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization Hepatol Baltim Md 59 1864-1873

[6] Ávila MA(2017)Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial Lancet Oncol 18 1624-1636

[7] Ayuso C(2018)SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-pacific patients with hepatocellular carcinoma J Clin Oncol 36 1913-1921

[8] Mínguez B(2019)Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma J Hepatol 71 1164-1174

[9] Varela M(2010)A proposed guideline for economic evaluation of health technologies Gac Sanit 24 154-170

[10] Kohn CG(2009)Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 b2535-372